Praxis Precision Medicines is no longer a discovery story. The Boston neuroscience company now sits between two Food and Drug Administration decisions and the first payroll of a commercial organization, and the equity already prices a large share of that conversion. Ulixacaltamide for essential tremor and relutrigine for two severe pediatric epilepsies both cleared mid-cycle reviews without a request for an advisory committee. Sponsor inspections closed with no Form 483 observations. That is the cleanest regulatory posture a pre-revenue issuer can show. The debate is whether that posture is already fully in the price, or whether the next stretch still has room to surprise.
The counterweight is not theoretical. Relutrigine's review clock already moved after the agency treated extra sensitivity analyses as a major amendment, pushing the target action date into late December. Vormatrigine, the once-daily sodium-channel candidate aimed at common adult epilepsy, missed its primary seizure-frequency endpoint in June even as a responder secondary landed and most treated patients stayed on drug. Overhead more than doubled as launch hiring and professional fees arrived ahead of any product sale. Cash and securities still sit near $1400 million after a January follow-on, which funds the plan into 2028. The buffer is real. So is the spend.
The next stretch resolves whether two late-cycle applications become two launches, and whether the commercial build stays inside the cash the company already raised. Relutrigine's December action date comes first. Ulixacaltamide's January date follows. A broad developmental-epilepsy readout sits between them. The investment question is simple: does the current capitalization still leave room for those events, or has the market already paid for a two-product company that does not yet sell a tablet?